| Literature DB >> 31595212 |
Arun K Ghosh1, Margherita Brindisi1.
Abstract
We have developed a conceptually new generation of non-peptidic HIV-1 protease inhibitors incorporating novel structural templates inspired by nature. This has resulted in protease inhibitors with exceptional potency and excellent pharmacological and drug-resistance profiles. The design of a stereochemically defined bis-tetrahydrofuran (bis-THF) scaffold followed by modifications to promote hydrogen bonding interactions with the backbone atoms of HIV-1 protease led to darunavir, the first clinically approved drug for treatment of drug resistant HIV. Subsequent X-ray crystal structure-based design efforts led us to create a range of exceptionally potent inhibitors incorporating other intriguing molecular templates possessing fused ring polycyclic ethers with multiple stereocenters. These structural templates are critical to inhibitors' exceptional potency and drug-like properties. Herein, we will highlight the synthetic strategies that provided access to these complex scaffolds in a stereoselective and optically active form, enabling our medicinal chemistry and drug development efforts.Entities:
Keywords: HIV-1 protease inhibitors; Natural products; cyclic ethers; drug discovery; synthesis
Year: 2018 PMID: 31595212 PMCID: PMC6781882 DOI: 10.1002/ajoc.201800255
Source DB: PubMed Journal: Asian J Org Chem ISSN: 2193-5807 Impact factor: 3.319